Table A2.
Dose regimens of the antibiotics used for model development and internal validation. The dose regimens are based on the transcription of the defined daily dosages of the beta-lactam antibiotics, into the prescribed dosages on the ICUs in the participating hospitals to establish the dose ranges in which the models are able to predict target non-attainment.
| Study Antibiotic | Median Dosage | Lower 95% CI Median Dosage | Upper 95% CI Median Dosage |
|---|---|---|---|
| Amoxicillin | 1000 mg q6h | 1000 mg q6h | 2000 mg q8h |
| Amoxicillin/clavulanic acid | 1000/200 mg q6h | 1000/200 mg q8h | 1000/200 mg q6h |
| Cefotaxime | 1000 mg q6h | 1000 mg q8h | 1000 mg q6h |
| Ceftazidime | 2000 mg q8h | 2000 mg q12h | 2000 mg q8h |
| Ceftriaxone | 2000 mg q24h | 2000 mg q24h | 2000 mg q24h |
| Cefuroxime | 1500 mg q8h | 1500 mg q8h | 1500 mg q8h |
| Flucloxacillin | 1000 mg q4h | 500 mg q.6.h | 2000 mg q4h |
| Meropenem | 1000 mg q8h | 1000 mg q8h | 1000 mg q8h |
| Piperacillin/tazobactam | 4000/500 mg q8h | 4000/500 mg q8h | 4000/500 mg q6h |